VitaNova Life Sciences Corporation
VNOV
$4.83
-$2.67-35.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 709.60K | 427.10K | 103.90K | 1.95M | 308.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 709.60K | 427.10K | 103.90K | 1.95M | 308.30K |
| Cost of Revenue | 393.30K | 166.30K | 35.10K | 795.80K | 119.00K |
| Gross Profit | 316.30K | 260.80K | 68.80K | 1.16M | 189.30K |
| SG&A Expenses | 269.60K | 161.60K | 101.20K | 75.10K | 80.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 662.90K | 327.90K | 136.30K | 870.90K | 199.40K |
| Operating Income | 46.70K | 99.20K | -32.40K | 1.08M | 108.90K |
| Income Before Tax | 46.70K | 99.30K | -32.40K | 1.08M | 108.30K |
| Income Tax Expenses | 91.10K | 63.50K | 13.90K | 280.40K | 35.30K |
| Earnings from Continuing Operations | -44.40K | 35.80K | -46.30K | 800.30K | 73.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.40K | 35.80K | -46.30K | 800.30K | 73.00K |
| EBIT | 46.70K | 99.20K | -32.40K | 1.08M | 108.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | 0.00 | -0.01 | 0.10 | 0.01 |
| Normalized Basic EPS | 0.00 | 0.01 | 0.00 | 0.08 | 0.01 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | 0.10 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.01 | 0.00 | 0.08 | 0.01 |
| Average Basic Shares Outstanding | 8.34M | 8.34M | 8.34M | 8.34M | 8.34M |
| Average Diluted Shares Outstanding | 8.34M | 8.34M | 8.34M | 8.34M | 8.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |